Effect of Ibandronate Therapy on Serum Chemerin, Vaspin, Omentin-1 and Osteoprotegerin (OPG) in Postmenopausal Osteoporotic Females

Abstract

Osteoporosis is a condition in which bone mineral density is reduced due to altered bone microstructure, which results in increased skeletal fragility and incidence of various types of fractures. Adipokines such as chemerin, vaspin, omentin-1 and osteoprotegerin are involved in bone remodeling. The current study was designed to determine the changes in circulating chemerin, vaspin, omentin-1, and osteoprotegerin levels after treatment with oral ibandronate 150 mg in postmenopausal osteoporotic females. The present study enrolled 107 postmenopausal osteoporotic females from a tertiary care hospital in Faisalabad, Pakistan, based on stringent inclusion and exclusion criteria. Sixty-six healthy postmenopausal, non-osteoporotic females with no systemic illness were chosen from the general population. The assessment of bone mineral density (BMD) was done using a DEXA scan. Serum levels of chemerin, vaspin, omentin-1 and osteoprotegerin were estimated using commercially available enzyme-linked immunosorbent assay kits. The collected data were analyzed with the Statistical Package for Social Sciences (SPSS) version 24. Following 6 months of ibandronate treatment, there was a significant decrease of 24.24% (p < .033) in serum chemerin levels, as well as a significant increase in serum vaspin levels 343.32% (p < .001) and osteoprotegerin levels 19.57% (p < .001), with no significant change in omentin-1 levels. Thus, an increase in serum chemerin levels and a decrease in serum vaspin and osteoprotegerin levels could be implicated in osteoporosis.

Chemerin and IL‐17 are potential predictors and Chemerin silencing alleviates inflammatory response and bone remodeling in chronic rhinosinusitis

“…Yet, it has been reported that there is a positive correlation between Chemerin and Th17 cell levels in asthmatic patients (Zhou et al, 2018), which hints at the participation of Chemerin in the inflammatory response of CRS. Also, animal and human studies have shown that plasma Chemerin level is correlated with bone remodeling (Han et al, 2021; Ramos‐Junior et al, 2017; Tariq et al, 2022). Bone remodeling is also unveiled to exist in CRS, and can be affected by IL‐17 (Khalmuratova et al, 2019; Khalmuratova & Shin, 2021).…”

The role of adipokines in osteoporosis management: a mini review

“…One study assessing the changes in plasma concentrations of chemerin, vaspin, omentin-1, and osteoprotegerin flowing treatment with ibandronate in post-menopausal patients with OP found a decrease of 24% following six months of treatment. Thus, suggesting an increase in circulating chemerin may be implicated in OP ( 58 ).…”

“…Another study, examining plasma concentrations of chemerin, vaspin, omentin-1, and osteoprotegerin following treatment with ibandronate in post-menopausal patients with OP found omentin-1 concentrations to have a positive relationship with BMD in post-menopausal individuals. Omentin-1 also predicted bone strength in the hip bone ( 58 ).…”

Association of osteoporosis risk and polymorphisms of osteoprotegerin gene T950C in postmenopausal Chinese women: A PRISMA-compliant meta-analysis

“…This suggests an important role of OPG in bone loss. [8] The authors have no funding and conflicts of interest to disclose. Research on OPG gene polymorphisms has also been carried out extensively, but there is still controversy about the effect of T950C on osteoporosis.…”